Oxurion NV — Major Shareholding Notification 2024

May 16, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

May 16, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000 shares of the then outstanding 10,101,777,808 shares, and therefore crossed below the threshold (10%) by virtue of the sale of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV	Backstage Communication
Pascal Ghoson	Jurgen Vluijmans
Chief Executive Officer	Partner
Pascal.ghoson@oxurion.com	jurgen@backstagecom.be

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

________

1) Status of the notification Final 2) Issuer Name OXURION Identification number 0881-620-924 3) Reason for the notification Acquisition or disposal of voting securities or voting rights 4) Notification bv A person that notifies alone 5) Persons subject to the notification requirement Address (for legal entitles) Name Atlas Special Opportunities LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577 6) Persons that dispose of votinq rights (only to be filled in If art 7 of the Law applies) Name Address (for legal entitles) Please continue entering the Information in part II concerning the persons referred to In Sections 5 and 6 Part II C 7) Date on which the threshold is crossed 13/05/2024 (DD/MMYYYY) 8) Threshold that is crossed (In %) 10 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10 9) Denominator 10,101,777,808 Please enter the denominator before filling in the data 10) Notified details Previous notification After the fransaction A) Voting rights # of voting rights % of voting rights # of voting rights Not linked to the Not linked to the Holders of voting rights Linked to securities Linked to securities securities securibes 0 9.91% 0.00% Atlas Special Opportunities LLC 1,467,712,295 1,000,850,000 0 TOTAL 1,000,850,000 9.91% 0.00%	FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Form TR-1 BE PART I	Transparency notification

TOTAL

Start with "groups" of holders. Add eutotals with E, and then finleh with the persons who are "alone".
For groups, start with the ultimate controlling natural person or l

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial Instrument	Expiration data	Exercise period or diste	# of voting rights that may be acquired if the Instrument Is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%

The zotais will be updated once you have cilcked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	1,000,850,000	9.91%

11) Full chain of controlled undertakings through which the holding is effectively held, It applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy votinq for only one GM

			Property of the program and the first of the first of the first of the first of the first of the first of the first
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

Cor 6 May 2024 (Wh setlement date on 8 May 2024), Alas Special Opportunities LC sold 10,000,000 stares in Ourin NT, as a real of Michilis datares (10,712,235 hares (13.5%, ﺍﻟﻤﺴﺎﺣﺔ 1 0 0 27 2017 11:52 AM #15 2017 14:47 PM #1 PM #1 PM #1 PM #1 12 0 Mar 1 13 M #12 Comments #1 11 11:20 am #1 11:50 am #1 11:50 am #1 1137.
17 07:50 PM #1201 List #1

Done at New York
On	15/05/2024 (DD/MM/YYYY)
Name & capacity Patrick Vance, proxyholder		Signature

For security reasons, the unsigned form in xlsx format should be
transmitted to transmits. You can do this manually
OR if you have MS Outlook at your disposal via the "Sav Send" button.

In addition, a signed copy in PDE format should also be transmitted.

Attachments

• EN
• NE